Skip to main content
. 2024 Mar 22;24:203. doi: 10.1186/s12887-024-04612-6

Table 2.

The comparison of treatments for high-risk patients with LCH

Initial treatment course I Initial treatment course II Continuation treatment
SCMC-LCH-2018 Group1

(W1-W6)

Pred 40 mg/m2 × 4w, taper 2w

VCR 1.5mg/m2 iv dl qw

Ara-C 100mg/m2 iv/IH d1-4 q2w(w1,3,5)

(W7-W22)

Pred 40 mg/m2 d1-5 q3w

VCR 1.5mg/m2 iv dl qw

Ara-C 100mg/m2 iv/IH d1-4 q3w

6-MP 50mg/m2/d, po, qn

(W25-W52)

Pred 40mg/m2 d1-5 q3w

VCR 1.5/m2 iv d1 q3w

Ara-C 100mg/m2 iv/H d1-4 q6w x3 times (w25,31.37)

6-MP 50mg/m2/d, po, qn
CCHG-LCH-2019

(W1-W6)

Pred 40 mg/m2 × 4w, taper 2w

VCR 0.05 kg/m2 iv day1 of w1,2,3,4,5,6

(W7-W30)

Pred 40mg/m2 d1-5 q3w

VCR 0.05 kg/m2 iv d1 q3w

Ara-C 150mg/m2 iv/IH d1-5 q3w

6-MP 50mg/m2/d, po, qn

(W31-W 52)

Pred 40mg/m2 d1-5 q3w

VCR 0.05 kg/m2 iv d1 q3w

6-MP 50mg/m2/d, po, qn
Histiocyte Society LCH-III trial

(W1-W6)

Pred 40 mg/m2 × 4w, taper 2w

VCR 6mg/m2 iv dl qw

(W7-W12)

Pred 40 mg/m2/d, d1-3 qw

VCR 6mg/m2 iv dl qw

(W13-W52)

Pred 40 mg/m2/d d1-5 q3w

VCR 6 mg/m2/d iv q3w

6-MP 50 mg/m2/d for 12 months